CSL is currently trading at a discount, even though it owns a leading global infrastructure for plasma-derived therapies that is difficult to replicate. The company is executing a Transformation Program aiming to reduce annual pre-tax costs by $500–$550 million by fiscal year 2028, with 60% of the savings for fiscal year 2026 already achieved. Growth in the Vifor segment is strong, balancing declines in the iron franchise, while new products like ANDEMBRY and HEMGENIX are expected to drive future growth. CSL's valuation remains attractive with a forward EV/EBITDA of 10.24x and forward P/S of 2.73x, presenting a compelling opportunity for patient investors despite some temporary operational challenges.
Dycom Industries reported a record first quarter with contract revenues up 56.1% to $1.965 billion and adjusted net income nearly doubling to $134.3 million. The company raised its full-year fiscal 2027 revenue outlook to $7.38-$7.65 billion, driven ...
BrewDog, part of Tilray Brands, is rolling out a major summer campaign across the UK tied to the global football tournament. The campaign features a "Win a Year of Beer" contest with special cans hidden in over 2.8 million packs at major retailers, p...
Autolus Therapeutics, a biopharmaceutical company specializing in next-generation T cell therapies, announced it will present at two upcoming investor conferences: William Blair’s Growth Stock Conference on June 2 and Jefferies Global Healthcare Conf...
Infrastructure Capital Advisors announced the first monthly dividend of $1 per share for its Infrastructure Capital Nasdaq Option Income ETF (QVOL), targeting an annualized distribution rate of 12-15%. The firm also declared monthly dividends for its...
G-III Apparel Group announced a quarterly cash dividend of $0.10 per share, payable on July 8, 2026, to shareholders of record as of June 22, 2026. This dividend reflects the company's ongoing commitment to returning value to its investors. G-III is ...
